Why Regeneron Pharmaceuticals (REGN) is One of the Top Gene Therapy Stocks to Buy According to Hedge Funds [Yahoo! Finance]
Regeneron Pharmaceuticals, Inc. (REGN)
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.regeneron.com
Company Research
Source: Yahoo! Finance
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) is one of the top gene therapy stocks to buy according to hedge funds . Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced on February 24 that the U.S. Food and Drug Administration (FDA) approved Dupixent® (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis with a history of sino-nasal surgery. Regeneron (REGN) Draws Higher Target From TD Cowen It reported that the FDA evaluated Dupixent under Priority Review for the treatment of AFRS, reserved for medicines that hold the potential to offer considerable improvements in the diagnosis, treatment, or prevention of serious conditions. Management stated that the approval expands Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) indications in sino-nasal diseases to now include AFRS, alongside chronic rhinosinusitis with nasal polyps. Kenneth Mendez, President and CEO, Asthma and Allergy Foundation of America (AAFA)
Show less
Read more
Impact Snapshot
Event Time:
REGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
REGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
News
- 2 Biotech Giants to Buy in 2026 [Yahoo! Finance]Yahoo! Finance
- Jim Cramer Says “I Should Have Pulled the Trigger on Regeneron” [Yahoo! Finance]Yahoo! Finance
- These 5 New York companies are among America's best employers [USA TODAY]USA TODAY
- Regeneron Pharmaceuticals (REGN) had its price target raised by Royal Bank Of Canada from $745.00 to $765.00. They now have a "sector perform" rating on the stock.MarketBeat
- Regeneron's Dupixent Win And Rare Disease Push Reshape Risk Reward Profile [Yahoo! Finance]Yahoo! Finance
REGN
Earnings
- 1/30/26 - Beat
REGN
Sec Filings
- 3/3/26 - Form 4
- 2/23/26 - Form 4
- 2/19/26 - Form 144
- REGN's page on the SEC website